{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:12Z","timestamp":1794023292102,"version":"4.8.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ectopic Adrenocorticotropic Hormone (ACTH) Syndrome (EAS) is a complex disorder caused by ACTH-producing tumors located outside the pituitary gland. EAS is most commonly associated with neuroendocrine neoplasms (NENs), rare malignancies category. Due to the nonspecific symptoms, EAS is often misdiagnosed, contributing to increased morbidity and complicating clinical management. In Italy, access to diagnostic and therapeutic resources for EAS and NENs varies significantly by region. As part of the 2024\u20132025 NIKE (Neuroendocrine Tumors, Innovation in Knowledge and Education) initiative, a multidisciplinary group, including endocrinologists, oncologists, pathologists, and nuclear medicine experts, designed a national survey to assess awareness, diagnostic approaches, and management of EAS in Italian centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 50-items structured questionnaire was developed, covering 3 sections: respondents\u2019 profile, diagnostic approaches, and treatment strategies. The survey was distributed as an anonymized form via email, with data collected from April to June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen Italian centers with NEN and EAS expertise participated. Most experts worked in European referral centers for rare tumors where the majority have an in-house, NEN-dedicated multidisciplinary team. Initial points of contact occurred most frequently in oncology (37.5%) and endocrinology (31.5%) clinics. A diagnostic delay was reported by 56% of respondent centers; hypokalemia was the most common presenting sign (93.8%). In 56.3% of centers, respondents reported that EAS was more commonly diagnosed before the detection of the underlying NEN, most frequently lung carcinoids or small\/large cell cancers (87.5%). Regarding diagnostic practices, 56.3% of centers indicated the use of the 1 mg dexamethasone suppression test (DST), followed by the high-dose DST. The desmopressin test was considered outdated or replaceable by 43.8% of respondents. Regarding therapeutic approaches, respondents reported that upfront surgery was performed in up to 50% of centers, with preoperative bridging pharmacological therapy used to achieve eucortisolism. Osilodrostat was the most frequently preferred first-line treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This survey provides a valuable snapshot of EAS care in Italy, highlighting both strengths and areas for improvement. The findings underscore the need for a national, more structured referral network to ensure timely diagnosis and access to specialized care. These insights may guide national protocol harmonization in EAS management and better alignment with international standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1690837","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:40Z","timestamp":1762492840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey"],"prefix":"10.3389","volume":"16","author":[{"given":"Alice","family":"Laffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Prinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Di Dato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Medici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gerardo Antonio","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2023.12.003","article-title":"A clinical perspective on ectopic Cushing\u2019s syndrome","volume":"35","author":"Ragnarsson","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14014","article-title":"The incidence of endogenous Cushing\u2019s syndrome in the modern era","volume":"91","author":"Wengander","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing\u2019s syndrome due to ectopic corticotropin secretion: twenty years\u2019 Experience at the national institutes of health","volume":"90","author":"Ilias","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1542","article-title":"The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up","volume":"91","author":"Isidori","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000314297","article-title":"Epidemiology of cushing\u2019s syndrome","author":"Steffensen","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac492","article-title":"Approach to the patient: diagnosis of cushing syndrome","volume":"107","author":"Savas","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302007000800007","article-title":"Ectopic ACTH syndrome","volume":"51","author":"Isidori","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B8","article-title":"Evaluation of 342 cases of mediastinal\/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties","volume":"5","author":"Soga","year":"1999","journal-title":"Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e13137","DOI":"10.1111\/jne.13137","article-title":"Distinguishing Cushing\u2019s disease from the ectopic ACTH syndrome: Needles in a haystack or hiding in plain sight","volume":"34","author":"Hayes","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-010-9139-z","article-title":"The ectopic ACTH syndrome","volume":"11","author":"Alexandraki","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-265","article-title":"Clinical features and management of ectopic ACTH syndrome at a single institute in Japan","volume":"57","author":"Doi","year":"2010","journal-title":"Endocr J"},{"key":"B12","first-page":"33","article-title":"Ectopic Cushing\u2019s syndrome: experience from a tertiary care centre","volume":"129","author":"Bhansali","year":"2009","journal-title":"Indian J Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz136","article-title":"Time to diagnosis in cushing\u2019s syndrome: A meta-analysis based on 5367 patients","volume":"105","author":"Rubinstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01260.x","article-title":"The limited value of the desmopressin test in the diagnostic approach to Cushing\u2019s syndrome","volume":"54","author":"Terzolo","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2021.41.6.521","article-title":"Second-line tests in the diagnosis of adrenocorticotropic hormone-dependent hypercortisolism","volume":"41","author":"Pinelli","year":"2021","journal-title":"Ann Lab Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac686","article-title":"Dynamic testing for differential diagnosis of ACTH-dependent cushing syndrome: A systematic review and meta-analysis","volume":"108","author":"Ceccato","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","first-page":"16","article-title":"Catheterization of the inferior petrosal sinus. Its role in the diagnosis of Cushing\u2019s syndrome. Experience with 23 explorations","volume":"53","author":"Bessac","year":"1992","journal-title":"Ann Endocrinol"},{"key":"B19","article-title":"One transient neurological complication (Sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of cushing\u2019s syndrome","volume":"84","author":"Lefournier","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0029","article-title":"Bilateral inferior petrosal sinus sampling","volume":"5","author":"Zampetti","year":"2016","journal-title":"Endocr Connect"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.4.6592-1","article-title":"Complications of inferior petrosel sinus sampling","volume":"85","author":"Kaltsas","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa409","article-title":"Non-invasive diagnostic strategy in ACTH-dependent cushing\u2019s syndrome","volume":"105","author":"Frete","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"luae255","DOI":"10.1210\/jcemcr\/luae255","article-title":"Successful treatment of severe ectopic ACTH-dependent cushing syndrome complicated by hypocalcemia with osilodrostat","volume":"3","author":"Lee","year":"2025","journal-title":"JCEM Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"luae008","DOI":"10.1210\/jcemcr\/luae008","article-title":"A case of an ectopic ACTH-producing tumor with adrenal shrinkage during osilodrostat administration","volume":"2","author":"Sawabe","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"luad101","DOI":"10.1210\/jcemcr\/luad101","article-title":"Successful management of cushing syndrome from ectopic ACTH secretion in an adolescent with osilodrostat","volume":"1","author":"Blew","year":"2023","journal-title":"JCEM Case Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic cushing syndrome: A real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.93.OC14","article-title":"Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term thERapy of endogenous Cushing\u2019s syndrome: preliminary results of the MOSKETEER study","author":"Detomas","year":"2023","journal-title":"Endocr Abstr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0967","article-title":"Diagnostic tests for Cushing\u2019s syndrome differ from published guidelines: data from ERCUSYN","volume":"176","author":"Valassi","year":"2017","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:20:42Z","timestamp":1762492842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1690837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"alternative-id":["10.3389\/fendo.2025.1690837"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1690837","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1690837"}}